[SCHEDULE 13G] NeuroOne Medical Technologies Corporation SEC Filing

Rhea-AI Filing Summary

Sio Capital Management, LLC reported beneficial ownership of 3,523,663 shares of NeuroOne Medical Technologies Corp common stock, equal to 7.07% of the outstanding shares (based on 49,817,835 shares outstanding as disclosed by the company). Sio holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power.

The filing states Sio acts as a registered investment adviser to funds that are the record owners of the shares and includes a disclosure that the GP and Michael Castor may be deemed to control the voting and dispositive decisions, although such beneficial ownership is expressly disclaimed. The filing also certifies the securities are held in the ordinary course of business and not to influence control of the issuer.

Positive

• Material stake disclosed: Sio reports ownership of 3,523,663 shares, representing 7.07% of outstanding common stock.
• Clear voting/dispositive detail: Filing specifies shared voting and shared dispositive power, with no sole power.
• Passive intent certified: Item 10 certifies the securities are held in the ordinary course and not to influence control of the issuer.

Negative

• None.

Insights

Financial Analyst

TL;DR: Sio holds a material passive stake of 7.07% (3.52M shares) with shared voting/dispositive power, disclosed under Schedule 13G.

The position size—3,523,663 shares representing 7.07% of the company's common stock—crosses the 5% materiality threshold and is therefore reportable. The filing indicates Sio's role as an investment adviser to funds that are the record owners and shows shared voting and dispositive power rather than sole control. Item 10's certification characterizes the holdings as acquired and held in the ordinary course and not for the purpose of changing control, consistent with a passive Schedule 13G disclosure.

Corporate Governance Expert

TL;DR: The disclosure highlights potential attribution via the GP and Michael Castor, with an explicit disclaimer of beneficial ownership.

The filing includes a footnote explaining Sio and Sio GP, LLC act as adviser and general partner to clients holding the reported shares, and notes that the GP and Michael Castor may be deemed to control voting and dispositive decisions; however, that potential attribution is expressly disclaimed. This dual statement is important for governance and attribution purposes: it notifies the market of possible control links while preserving the parties' formal disclaimers. The overall filing is a routine, material disclosure of a passive position.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NeuroOne Medical Technologies Corp

(Name of Issuer)

Common Stock, par value, $0.001 per share

(Title of Class of Securities)

64130M209

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 64130M209

1

Names of Reporting Persons

Sio Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,523,663.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,523,663.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,523,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.07 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: 1 As of June 30, 2025, Sio Capital Management, LLC beneficially owned 3,523,663 shares of Common Stock with shared voting power and shared dispositive power. 2 Based upon 49,817,835 Common Shares outstanding as of May 9, 2025, as disclosed by the Issuer's 10-Q on May 13, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NeuroOne Medical Technologies Corp
(b)	Address of issuer's principal executive offices: 7599 Anagram Dr., Eden Prairie, MN, 55344
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)	Address or principal business office or, if none, residence: 600 Third Avenue, 2nd Floor New York, New York 10016
(c)	Citizenship: Sio is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value, $0.001 per share
(e)	CUSIP No.: 64130M209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,523,663
(b)	Percent of class: 7.07%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,523,663 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,523,663 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sio Capital Management, LLC

Signature:	/s/ Jin W. Lee
Name/Title:	Chief Compliance Officer
Date:	08/13/2025

FAQ

How many NeuroOne (NMTC) shares does Sio Capital own?

Sio Capital Management, LLC beneficially owns 3,523,663 shares of NeuroOne common stock according to the Schedule 13G.

What percentage of NMTC does Sio Capital's stake represent?

The reported stake represents 7.07% of NeuroOne's outstanding common stock, based on 49,817,835 shares disclosed by the issuer.

Does Sio Capital have sole voting or dispositive power over the NMTC shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power, and 3,523,663 shares with shared voting and dispositive power.

Was the position reported as passive or active in the filing?

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control, consistent with a passive Schedule 13G disclosure.

Who signed the Schedule 13G on behalf of Sio Capital?

The statement is signed on behalf of Sio Capital Management, LLC by Jin W. Lee, Chief Compliance Officer.